Study 2 Sample Clauses

Study 2. 1 3 Klinické hodnocení The clinical study known as A Multicenter, Randomized, Double-blind, Xxxxxxx-xxxxxxxxxx Xxxxx 0
Study 2. Question 12 from study 2 provided some ideas to make the games even better. These ideas are listed in Table 21. Formulation of questions (only one answer should be possible in order to avoid any discussion with pupils) 4 Formulation of questions (only one answer should be possible in order to avoid any discussion with pupils) 3 Less applicable in large groups 5 Time pressure 5 More variation in the different kinds of questions 2 Preparation for an examination / temporary evaluation 2 Some pupils might lose their motivation in the second round 4 An equal amount of questions for each team 5 Time pressure 1 Pupils will shout the answers or cheat 2 Pupils have to think about posing the right question (perceived as more difficult, good exercise) 2 In regards to Bingo, many teachers recommended to include an extra round of questions during the second round with the same numbers in order to avoid a lack of motivation for the students who were not able to answer every question right. Another solution for this problem was to let students shout ‘bingo’ after obtaining a full row instead of the whole card. We think that the teachers had a valid point and we would take the second solution into consideration. Timing also seemed to be an issue for some teachers: they found that the time was not used efficiently because it took a lot of time to spin the wheel. This problem might be solved by using a bowl with numbers in it or to call out random numbers. There was even a teacher that already used Bingo in their class. Another teacher came up with the idea to include a score that would reflect the level of the individual pupils, this might be a good idea especially when the teacher wants to find out who is struggling and which parts of the material are perceived to be more difficult. One teacher found Xxxxx ideal for the last class before a recess and another one suggested to let pupils play the game at home. In regard to the Jeopardy game, the teachers also pointed out the importance of the formulation of questions. It is important that there is only one possible answer in order to avoid any discussion with pupils. We on the other hand think that the different answers of the students show that they have gained insight in the material, which is exactly one of our purposes that were achieved for both studies. Furthermore, Xxxxxxx and Xxxxx (1991) found that discussion is preferred above a normal lecture. Two teachers had the impression that the Jeopardy game had a higher in...
Study 2. 1 3 Klinické hodnocení The clinical study known as A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3
Study 2. Teachers Table 14Descriptive Statistics Teachers and One-Sample T-Test with Test Value = 3 General questions N Mean Maximu m Minimu m SD T p-value (one- sided) Table 15 – Results General Questionnaire Teachers General questions 1 = Never 2 = Less than once per month 3 = 1 to 3 times per month 4 = Weekly 5 = Each class
Study 2. In Study 1, participants viewed the employment of a relative as less deserving than the employment of an unrelated target, regardless of the relative’s described competence. This is incongruent with the principle of meritocracy, which is frequently referred to in opposition to nepotism. The meritocracy principle reflects distributive fairness, which revolves around the fairness of outcome distributions (Son Hing et al., 2011). In a distributively fair world, the ratio between a person's input (e.g., competence) and outcome (e.g., employment) should equate the ratio of input and outcome for relevant comparison others (Xxxxx, 1965). Based on this principle of fairness, people should only view the employment of kin as less distributively fair when involving incompetent kin (Hypothesis 3), because competent kin is as deserving as competent people without family ties. However, as shown in Study 1, the fact that people viewed the employment of kin as undeserving regardless of competence suggests that there is more than meritocracy when people evaluate the employment of kin. From the perspective of the group engagement model of procedural justice (Xxxxx & Blader, 2003), people would evaluate the employment of kin not only in light of meritocracy but also in terms of the procedure by which such employment decisions are made. Employees need a sense of procedural fairness because it conveys their belongingness to the organization. Belongingness is important because it provides employees with a sense of meaning, connectedness, self-esteem, and certainty (Xxxxxxxx & Xxxx, 1989; Xxxx et al., 2008). The extent to which organizational members are treated in a procedurally fair way by their organization reflects the degree to which they are valued by the organization (xxx xxx Xxx et al., 2001). If employees do not feel being valued by—and belong to—the organization they work for, they are more likely to exhibit counterproductive behaviors as means of protest, they are less willing to engage in extra-role behaviors (e.g., help co- workers), and they are likely to show low job satisfaction and commitment to the organization (Xxxxxx & Xxxxx, 2009; Xxxxxxx, 2005). Such negative consequences make it imperative that we learn more about the impact of nepotism on employees perceived procedural fairness. The literature on in-group favoritism suggests that people expect and believe that members of a group (including a family) would favor their own members over non-members (Xxxxxxx ...
Study 2. Non-Treatment Seeking Sample

Related to Study 2

  • Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: minimum 21 days/3 weeksuntil patient's weight >2000g, averaged 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months following enterostomy closure (12- month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 months of overall study duration).

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Design This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.

  • The Study 1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Phase 2 Phase 2 is expected to consist of Member Nodes and a select number of Nodes operated by non-Members. The non-Member Nodes will be required to comply with Node hosting terms as set forth by the Council, which may be amended from time to time (the “General Node Terms”).

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;